Jennifer Wellman - Spark Therapeutics Insider

ONCE -- USA Stock  

USD 81.25  0.83  1.01%

Ms. Jennifer Wellman is CoFounder and Head of Regulatory Strategy of Spark Therapeutics Inc. Prior to joining Spark Ms. Wellman was the Director of Regulatory Interactions for Gene Therapy Studies at the Center for Cellular and Molecular Therapeutics at CHOP. Ms. Wellman also previously held a role as Associate Scientist at Avigen Inc
Age: 36  Founder Since 2013      
Wellman holds a B.S. in microbiology and immunology from Queen?s University and an M.S. from the University of New Haven.

Management Efficiency

The company has return on total asset (ROA) of (28.14) % which means that it has lost $28.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.37) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 35.75 M in liabilities with Debt to Equity (D/E) ratio of 7.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has Current Ratio of 11.13 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 315 people.Spark Therapeutics (ONCE) is traded on BATS Exchange in USA. It is located in PENNSYLVANIA U.S.A and employs 315 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Spark Therapeutics Leadership Team

Romuald Corbau, Translational Research Lead
Carol GrevePhilips, Head of Business Development and Strategy
Robert Perez, Director
Lars Ekman, Independent Director
Jennifer Wellman, Co-Founder and Head of Regulatory Strategy
Fraser Wright, Co-Founder and CTO
Morgan Molloy, Head of U.S. Commercial
Lorris Betz, Director
Joseph Barge, General Counsel and Head of Business Administration
Katherine High, President Chief Scientific Officer, Director
Elliot Sigal, Independent Director
John Furey, COO
Vincent Milano, Independent Director
Lota Zoth, Director
Rogerio Coelho, Chief Commercial Officer
Elliott Sigal, Independent Director
Guang Qu, Head of Process Development
Daniel Takefman, Head of Regulatory Affairs
Stephen Webster, CFO
Rogerio Vivaldi, Chief Commercial Officer
Diane Blumenthal, Head of Technical Operations
Jeffrey Marrazzo, CEO, Co-Founder, Director
Daniel Faga, Chief Business Officer
Anand Mehra, Independent Director
Linda Hearne, Financial Operations and Analysis Lead
Paul Gil, Regulatory CMC and Quality Assurance Lead
Charles Sigal, Independent Director
Federico Mingozzi, Chief Scientific Officer
Steven Altschuler, Chairman of the Board
Lisa Dalton, Head - Human Resources

Stock Performance Indicators

Current Sentiment - ONCE

Spark Therapeutics Investor Sentiment
Most of Macroaxis users are now bullish on Spark Therapeutics. What is your outlook on investing in Spark Therapeutics? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally take a look at Your Equity Center. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.